在复杂场景中管理HIT的方法,包括心脏手术
Oluwatayo Adeoye1, Guoliang Zheng2, Oluwatoyosi A Onwuemene3
1Department of Medicine, St Elizabeth's Medical Center, Boston, MA.
Hematology. American Society of Hematology. Education Program
|December 7, 2024
概括
在心脏手术和耐火病例中,治疗肝素诱导的血小板缺血 (HIT) 是复杂的. 虽然证据有限,但治疗性血交换 (TPE) 和rituximab等替代策略也得到了审查.
科学领域:
- 血液学 血液学 血液学
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
背景情况:
- 肝素诱导的血小板缺血 (HIT) 带来了重大管理挑战.
- 标准的HIT治疗 (氨酸停止和非氨酸抗凝剂) 可能对特定的患者群体不足.
研究的目的:
- 审查复杂患者群体中HIT的替代管理策略.
- 探索心脏手术患者,耐火性HIT患者和有活跃出血的患者的选择.
主要方法:
- 对替代性HIT疗法的临床经验和文献的审查.
- 分析包括治疗性血交换 (TPE),抗血小板疗法,静脉注射免疫球蛋白,rituximab和血小板输血风险的策略.
主要成果:
- 对于使用TPE或抗血小板治疗的心脏手术患者的肝素再暴露,临床经验有限.
- 静脉注射的免疫球蛋白,TPE和rituximab被认为是耐火性HIT.
- 对活跃出血患者的出血管理和血小板输血风险进行讨论.
结论:
- 在复杂场景中存在替代HIT管理策略,但证据有限.
- 以患者为中心的方法需要仔细考虑这些替代疗法的风险和益处.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468
Introduction to Hemostasis
5.6K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.6K
Health Information Technology and Healthcare Information System
799
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
799
Extrinsic and Intrinsic Pathways of Hemostasis
5.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.5K


